Pluristem to present PLX-PAD cell data later this month

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem Therapeutics (PSTI +4.7%) gets an early lift from an announcement that the company will present results of a Phase 1/2 clinical trial of PLX-PAD cells for the treatment of muscle injury on January 21.

"Data from this clinical trial will give us information regarding other potential surgical orthopedic injuries and non-surgical sports related injuries for which our PLX-PAD cells may be beneficial," CEO Zami Aberman says. (PR)